These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 35503103

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
    Grünert SC, Elling R, Maag B, Wortmann SB, Derks TGJ, Hannibal L, Schumann A, Rosenbaum-Fabian S, Spiekerkoetter U.
    Orphanet J Rare Dis; 2020 Aug 24; 15(1):218. PubMed ID: 32838757
    [Abstract] [Full Text] [Related]

  • 5. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
    Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M.
    Blood; 2020 Aug 27; 136(9):1033-1043. PubMed ID: 32294159
    [Abstract] [Full Text] [Related]

  • 6. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
    Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ, Zhou ZZ, Zeng CH, Tao CY, Liu ZC, Zhang W, Liu L.
    Orphanet J Rare Dis; 2024 Apr 11; 19(1):155. PubMed ID: 38605407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
    Dale DC, Bolyard AA, Marrero T, Kelley ML, Makaryan V, Tran E, Leung J, Boxer LA, Kishnani PS, Austin S, Wanner C, Ferrecchia IA, Khalaf D, Maze D, Kurtzberg J, Zeidler C, Welte K, Weinstein DA.
    Curr Opin Hematol; 2019 Jan 11; 26(1):16-21. PubMed ID: 30451720
    [Abstract] [Full Text] [Related]

  • 9. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
    Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR.
    Orphanet J Rare Dis; 2022 May 12; 17(1):195. PubMed ID: 35549996
    [Abstract] [Full Text] [Related]

  • 10. [Investigation on the treatment of empagliflozin in glycogen storage disease type Ⅰb].
    Jiang JJ, Ma MS, Wei M, Qiu ZQ.
    Zhonghua Er Ke Za Zhi; 2024 Jun 02; 62(6):526-529. PubMed ID: 38763873
    [Abstract] [Full Text] [Related]

  • 11. Case report: The success of empagliflozin therapy for glycogen storage disease type 1b.
    Klinc A, Groselj U, Mlinaric M, Homan M, Markelj G, Mezek Novak A, Sirca Campa A, Sikonja J, Battelino T, Zerjav Tansek M, Drole Torkar A.
    Front Endocrinol (Lausanne); 2024 Jun 02; 15():1365700. PubMed ID: 38919482
    [Abstract] [Full Text] [Related]

  • 12. Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib.
    Grünert SC, Rosenbaum-Fabian S, Schumann A, Selbitz AC, Merz W, Gieselmann A, Spiekerkoetter U.
    JIMD Rep; 2022 Jul 02; 63(4):303-308. PubMed ID: 35822091
    [Abstract] [Full Text] [Related]

  • 13. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.
    Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y, Ma N, Lan J, Zhang Y, Niu H, Shang L, Jiang X, Yang M.
    Sci Rep; 2024 Apr 15; 14(1):8630. PubMed ID: 38622211
    [Abstract] [Full Text] [Related]

  • 14. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.
    Kaczor M, Malicki S, Folkert J, Dobosz E, Bryzek D, Chruscicka-Smaga B, Greczan M, Wesół-Kucharska D, Piątosa B, Samborowska E, Madzio J, Książyk J, Ehmke Vel Emczyńska E, Hajdacka M, Potempa J, Młynarski W, Rokicki D, Veillard F.
    Blood Adv; 2024 Jun 11; 8(11):2790-2802. PubMed ID: 38531056
    [Abstract] [Full Text] [Related]

  • 15. Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation.
    Küçükçongar Yavaş A, Engin Erdal A, Bilginer Gürbüz B, Ünlüsoy Aksu A, Kasapkara ÇS.
    J Pediatr Endocrinol Metab; 2023 Nov 27; 36(11):1092-1099. PubMed ID: 37791580
    [Abstract] [Full Text] [Related]

  • 16. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
    Maiorana A, Tagliaferri F, Dionisi-Vici C.
    Front Endocrinol (Lausanne); 2023 Nov 27; 14():1145111. PubMed ID: 37152929
    [Abstract] [Full Text] [Related]

  • 17. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I.
    Visser G, Rake JP, Fernandes J, Labrune P, Leonard JV, Moses S, Ullrich K, Smit GP.
    J Pediatr; 2000 Aug 27; 137(2):187-91. PubMed ID: 10931410
    [Abstract] [Full Text] [Related]

  • 18. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.
    Tallis E, Karsenty CL, Grimes AB, Karam LB, Elsea SH, Sutton VR, Rawls-Castillo BL, Liu N, Soler-Alfonso C.
    JIMD Rep; 2022 Jul 27; 63(4):309-315. PubMed ID: 35822097
    [Abstract] [Full Text] [Related]

  • 19. [Short-term efficacy of empagliflozin in children with glycogen storage disease type Ⅰb].
    Jiang JJ, Zheng X, Ma MS, Cui XG, Jian S, Tang XY, Bao XD, Zhang SM, Ma JR, Song HM, Qiu ZQ.
    Zhonghua Er Ke Za Zhi; 2023 Jun 02; 61(6):515-519. PubMed ID: 37312462
    [Abstract] [Full Text] [Related]

  • 20. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b.
    Calderwood S, Kilpatrick L, Douglas SD, Freedman M, Smith-Whitley K, Rolland M, Kurtzberg J.
    Blood; 2001 Jan 15; 97(2):376-82. PubMed ID: 11154211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.